SLNO FY2025 EPS Forecast Decreased by Cantor Fitzgerald
Equities researchers at Cantor Fitzgerald lowered their FY2025 EPS estimates for Soleno Therapeutics in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska ...
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?
We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno Therapeutics (NASDAQ:SLNO) Trading Up 3.9% Following Analyst Upgrade
Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...
Soleno Therapeutics price target raised to $81 from $70 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Soleno Therapeutics (SLNO) to $81 from $70 and keeps a Buy rating on ...
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?
We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...
Explore more
Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger
Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by ...
Investor's Business Daily on MSN3d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...